Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. [artículo]
Por: Ruilope Urioste, Luis Miguel [Nefrología]
| Salazar, Jorge [Nefrología] | Segura de la Morena, Julián [Nefrología].
Colaborador(es): Servicio de Nefrología.
Editor: Expert opinion on investigational drugs, 2013Descripción: 22(7):915-25.Recursos en línea: Solicitar documento Resumen: INTRODUCTION: Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New drugs with different efficacy and effectiveness to control cardiovascular and renal disease are always welcomed.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC190 (Navegar estantería) | Disponible |
Formato Vancouver:
Segura J, Salazar J, Ruilope LM. Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opin Investig Drugs. 2013 Jul;22(7):915-25.
PMID: 23731190
Contiene 58 referencias
INTRODUCTION: Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New drugs with different efficacy and effectiveness to control cardiovascular and renal disease are always welcomed.
No hay comentarios para este ejemplar.